权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors

GPR35 和 GPR55（假定的大麻素受体）的分子表征

基本信息

批准号：
7864275
负责人：
MARY E ABOOD
金额：
$ 31.77万
依托单位：
TEMPLE UNIV OF THE COMMONWEALTH
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-07-15 至 2012-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7864275
关键词：
Adenylate Cyclase Affinity Agonist Amino Acids Binding CNR1 gene CNR2 gene Calcium Cannabinoids Cells Charge Communities Computer Simulation Computers Data Docking Drug Receptors Drug abuse Drug or chemical Tissue Distribution Endocannabinoids G-Protein-Coupled Receptors GTP-Binding Proteins Generations Goals Herb In Vitro Indoles Institutes Knowledge Ligand Binding Ligands Literature Marijuana Mediating Memory Messenger RNA Microglia Mitogen-Activated Protein Kinases Modeling Molecular Molecular Conformation Molecular Models Molecular Profiling Mus Mutate Mutation Nature Neurons Organ Pathway interactions Peripheral Peripheral Nervous System Phosphotransferases Physiological Physiological Processes Property Proteins Pyrazoles Radiolabeled Receptor Activation Regulation Reporting Research Research Personnel Reverse Transcriptase Polymerase Chain Reaction Role SR 141716A Scheme Second Messenger Systems Signal Pathway Signal Transduction Signal Transduction Pathway Simulate Site Site-Directed Mutagenesis Structure TRPV1 gene Techniques Testing Time Transmembrane Domain Western Blotting Work base cannabinoid receptor capsaicin receptor design dioleoylphosphatidylcholine experience functional group human GPRC5C protein immunocytochemistry in vivo interest molecular dynamics molecular modeling mutant novel programs protein activation radiotracer receptor receptor binding receptor expression research study second messenger tool

项目摘要

DESCRIPTION (provided by applicant): A large number of physiological processes are controlled by the endogenous cannabinoids. Most of these effects have been attributed to action at either the cannabinoid CB1 or CB2 receptors. Yet there are effects that clearly are not CB1- or CB2-mediated which may not be receptor mediated, but there is also sufficient evidence to suggest the involvement of the vanilloid receptor (TRPV1) in cannabinoid effects and at least two other cannabinoid receptor subtypes defined only pharmacologically until now. Very recently, two orphan G-protein coupled receptors (GPCRs), GPR35 and GPR55, have been suggested to be cannabinoid receptors, with a fairly wide range of cannabinoid ligands reported to display affinity/efficacy at each. We have cloned and expressed both GPR35 and GPR55 and our preliminary studies confirm that they are activated by multiple cannabinoid compounds. In work proposed here, we plan to characterize these two GPCRs through ligand binding and functional studies. Recently developed computer models of GPR35 and GPR55 in their inactive and activated states will be used to guide mutation studies of each receptor. These models are informed by our extensive modeling and mutation experience with the cannabinoid CB1 and CB2 receptors. The goal of mutation studies will be not only to identify residues involved in ligand recognition, but also those residues important for receptor activation. In GPR35 and GPR55 ligand recognition studies, the involvement of specific amino acids with specific ligand functional groups will be tested using carefully chosen compounds. Results of mutation studies in vitro will be used to refine computer receptor models, such that at any given time, these models reflect the current state of knowledge in the field. Because work thus far on GPR35 and GPR55 has not identified a high affinity antagonist for either receptor and because such antagonists would be very valuable tools for studying these two receptors, another goal of the proposed work will be to design antagonists for each receptor sub-type. These compounds will be designed at UNCG (Reggio), synthesized at Research Triangle Institute (Seltzman), and evaluated at CPMCRI (Abood). High affinity antagonists that emerge from this work will be radiolabeled and made available to the scientific community. Determining the distribution of GPR35 and signal transduction pathways of GPR35 and GPR55 will help define their physiological and pathophysiological roles.

描述（申请人提供）：大量的生理过程是由内源性大麻素控制的。这些影响大多归因于大麻素CB1或CB2受体的作用。然而，有一些作用显然不是CB1或cb2介导的，也可能不是受体介导的，但也有足够的证据表明，香草受体（TRPV1）参与大麻素的作用，至少有两种其他的大麻素受体亚型直到现在才被药理学定义。最近，两种孤儿g蛋白偶联受体（GPR35和GPR55）已被认为是大麻素受体，并且报道了相当广泛的大麻素配体对每种大麻素都表现出亲和力/功效。我们已经克隆并表达了GPR35和GPR55，我们的初步研究证实它们被多种大麻素化合物激活。在本文提出的工作中，我们计划通过配体结合和功能研究来表征这两种gpcr。最近开发的GPR35和GPR55在失活和激活状态下的计算机模型将用于指导每种受体的突变研究。这些模型是通过我们对大麻素CB1和CB2受体的广泛建模和突变经验得出的。突变研究的目标不仅是识别参与配体识别的残基，而且还包括那些对受体激活重要的残基。在GPR35和GPR55配体识别研究中，将使用精心选择的化合物来测试特定氨基酸与特定配体官能团的关系。体外突变研究的结果将用于改进计算机受体模型，以便在任何给定的时间，这些模型都能反映该领域的当前知识状态。由于到目前为止，对GPR35和GPR55的研究还没有发现对这两种受体具有高亲和力的拮抗剂，而且这些拮抗剂将是研究这两种受体的非常有价值的工具，因此提出的工作的另一个目标将是为每种受体亚型设计拮抗剂。这些化合物将在UNCG （Reggio）设计，在Research Triangle Institute （Seltzman）合成，并在CPMCRI （Abood）进行评估。从这项工作中产生的高亲和力拮抗剂将被放射性标记并提供给科学界。确定GPR35的分布及GPR35和GPR55的信号转导途径有助于明确其生理和病理生理作用。